Health
ERS Genomics and Applied StemCell sign agreement on commercialization of CRISPR gene editing tools – News-Medical.net
ERS Genomics Limited, which was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property (IP) co-owned by Dr. Emmanuelle Charpentier, today announced it has signed an agreement with Applied StemCell, Inc., a leading provider of ste…
ERS Genomics Limited, which was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property (IP) co-owned by Dr. Emmanuelle Charpentier, today announced it has signed an agreement with Applied StemCell, Inc., a leading provider of stem cell, animal model, antibody discovery services and reagents.
ERS Genomics holds an exclusive worldwide license from Dr. Charpentier to the foundational patents covering CRISPR/Cas9. Companies can obtain licenses to this technology for in…
-
General22 hours agoPoliticians asked how to Trump-proof Australia’s fragile economy on Q+A
-
Noosa News22 hours agoNew self-serve style chip shop, Chip ‘n’ Mix, in Noosa becomes an instant obsession
-
Noosa News14 hours agoSunshine Coast police disappointed by drink drivers in school zone
-
General22 hours agoAsia stocks plunge, HK suffers steepest fall since 1997